Fecal bacteriotherapy for recurrent Clostridium difficile infection - PubMed (original) (raw)
Review
Fecal bacteriotherapy for recurrent Clostridium difficile infection
Johan S Bakken. Anaerobe. 2009 Dec.
Abstract
Clostridium difficile infection (CDI) has emerged as a major complication associated with the use of systemic antimicrobial agents. Broad-spectrum antimicrobial agents disrupt the ecological bacterial balance in the colon and create an opportunity for C. difficile overgrowth with attendant production of toxins and clinical symptoms of colitis. Recommended therapies for CDI include oral administration of metronidazole or vancomycin for 10-14 days. However, 5% to 35% of patients experience infection relapse after completion of treatment. Recently, patients who failed to resolve their infection with conventional therapies and went on to develop chronic relapsing CDI were successfully treated with fecal bacteriotherapy. Stool obtained from a healthy individual was instilled from either end of the GI tract. Although the published experience with fecal bacteriotherapy is still limited, the published treatment results for 100 patients have demonstrated an average success-rate close to 90%. Fecal bacteriotherapy is a low tech procedure which is easy to perform, and breaks the cycles of repeated antibiotic use, which in turn reduces the risk of antibiotic associated resistance and adds potential cost savings when compared to repeated antibiotic administration and hospitalizations.
Similar articles
- Fecal microbiota transplantation for relapsing Clostridium difficile infection in 26 patients: methodology and results.
Kelly CR, de Leon L, Jasutkar N. Kelly CR, et al. J Clin Gastroenterol. 2012 Feb;46(2):145-9. doi: 10.1097/MCG.0b013e318234570b. J Clin Gastroenterol. 2012. PMID: 22157239 - Fecal microbiota transplantation for recurrent clostridium difficile infection.
Brandt LJ, Reddy SS. Brandt LJ, et al. J Clin Gastroenterol. 2011 Nov;45 Suppl:S159-67. doi: 10.1097/MCG.0b013e318222e603. J Clin Gastroenterol. 2011. PMID: 21992957 Review. - Fecal bacteriotherapy for relapsing Clostridium difficile infection in a child: a proposed treatment protocol.
Russell G, Kaplan J, Ferraro M, Michelow IC. Russell G, et al. Pediatrics. 2010 Jul;126(1):e239-42. doi: 10.1542/peds.2009-3363. Epub 2010 Jun 14. Pediatrics. 2010. PMID: 20547640 - Clostridium difficile colitis.
Efron PA, Mazuski JE. Efron PA, et al. Surg Clin North Am. 2009 Apr;89(2):483-500, x. doi: 10.1016/j.suc.2008.09.014. Surg Clin North Am. 2009. PMID: 19281896 - Best strategies in recurrent or persistent Clostridium difficile infection.
Cocanour CS. Cocanour CS. Surg Infect (Larchmt). 2011 Jun;12(3):235-9. doi: 10.1089/sur.2010.080. Epub 2011 Jul 18. Surg Infect (Larchmt). 2011. PMID: 21767157 Review.
Cited by
- Microbiota restoration therapies for recurrent Clostridioides difficile infection reach an important new milestone.
DuPont HL, DuPont AW, Tillotson GS. DuPont HL, et al. Therap Adv Gastroenterol. 2024 May 24;17:17562848241253089. doi: 10.1177/17562848241253089. eCollection 2024. Therap Adv Gastroenterol. 2024. PMID: 38800353 Free PMC article. Review. - The Intestinal and Skin Microbiome in Patients with Atopic Dermatitis and Their Influence on the Course of the Disease: A Literature Review.
Mazur M, Tomczak H, Łodyga M, Plagens-Rotman K, Merks P, Czarnecka-Operacz M. Mazur M, et al. Healthcare (Basel). 2023 Mar 6;11(5):766. doi: 10.3390/healthcare11050766. Healthcare (Basel). 2023. PMID: 36900771 Free PMC article. Review. - The contribution of the gut-liver axis to the immune signaling pathway of NAFLD.
Liu J, Wu A, Cai J, She ZG, Li H. Liu J, et al. Front Immunol. 2022 Aug 31;13:968799. doi: 10.3389/fimmu.2022.968799. eCollection 2022. Front Immunol. 2022. PMID: 36119048 Free PMC article. Review. - Any Future for Faecal Microbiota Transplantation as a Novel Strategy for Gut Microbiota Modulation in Human and Veterinary Medicine?
Takáčová M, Bomba A, Tóthová C, Micháľová A, Turňa H. Takáčová M, et al. Life (Basel). 2022 May 12;12(5):723. doi: 10.3390/life12050723. Life (Basel). 2022. PMID: 35629390 Free PMC article. Review. - Clostridioides difficile infection and One Health: an equine perspective.
Hain-Saunders NMR, Knight DR, Bruce M, Riley TV. Hain-Saunders NMR, et al. Environ Microbiol. 2022 Mar;24(3):985-997. doi: 10.1111/1462-2920.15898. Epub 2022 Jan 21. Environ Microbiol. 2022. PMID: 35001483 Free PMC article. Review.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical